Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Celltrion Inc logo — Built on Trust, Toward Innovation

Celltrion Inc

Built on Trust, Toward Innovation

Founded 2002 Korea South Korea South 2596 employees IPO Total: $1.23B Biotechnology, Pharmaceutical

General Information

Company Name Celltrion Inc
Founded Year 2002
Location Korea South Korea South
Employees 2596
Industries Biotechnology, Pharmaceutical
Funding Stage IPO
Business Model B2B, D2C, B2B2C
Revenue Model Product Sales, Licensing, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Celltrion Inc. To contact Celltrion Inc, visit celltrion.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Celltrion Inc compare?

A PDF of Celltrion Inc and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Celltrion Inc soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Celltrion Inc

Celltrion Inc, operating under the slogan "Built on Trust, Toward Innovation", is a pioneering entity in the biotechnology and pharmaceutical industries. Founded in 2002 and headquartered in Korea South, the company is distinguished for its comprehensive biopharmaceutical capabilities that span from research and development to distribution.

Specializing in monoclonal antibody (mAb) biosimilars, Celltrion is dedicated to addressing unmet medical needs with advanced, antibody-based biologics. The company boasts a robust business model that prioritizes efficiency, quality, and innovation, ensuring widespread access to life-changing therapies.

Their recent financial milestone includes securing a substantial $720.00M in Post IPO Equity investment on 01 July 2025. This funding is expected to support their commitment to advancing medical treatments and enhancing patient care on a global scale. Celltrion exemplifies a strategic partner, co-creating value throughout the healthcare journey.

Business keywords: Biopharmaceuticals, Monoclonal Antibody Biosimilars, Therapeutic Proteins, Innovative Medications, Affordable Therapies, Unmet Medical Needs, Biologics, End-to-End Capabilities, R&D, Distribution, Customer Intimacy, Advanced Therapies, Healthcare Access, Biosimilar Development, Oncology

Services & Products

Research and Development (R&D)
Clinical Trials
Manufacturing and Production
Regulatory Affairs
Distribution and Sales

Target Customers

Healthcare Providers Patients Pharmacy Benefit Managers (PBMs) Government Health Agencies Pharmaceutical Companies

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity $720.00M -
01 Jul 2025
Post-IPO Equity $320.00M 1
Scuti Capital Management
01 Oct 2023
Post-IPO Equity $129.00M 1
Temasek
01 Jun 2013
IPO Undisclosed -
01 Jul 2005
Early VC $59.40M 2
KT&G Corporation
KT&G Corporation, VaxGen
01 Mar 2002

Celltrion Inc Alternatives & Competitors

View All Alternatives
Celltrion Inc vs
Differentiated Therapeutics Inc
Differentiated Therapeutics Inc United States

What if you could predict molecules to make the cause of disease disappear?

Seed
3 employees
Biotechnology, Health and Wellness
Celltrion Inc vs
BlossomHill Therapeutics, Inc.
BlossomHill Therapeutics, Inc. United States

Addressing urgent unmet medical needs through deeper science, true originality, and rich experience....

Series B
69 employees
Biopharma, Biotechnology
Celltrion Inc vs
Genmab
Genmab Denmark

Differentiated human antibody therapeutics for the treatment of cancer

IPO
2981 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About Celltrion Inc

Built on Trust, Toward Innovation
Celltrion Inc was founded in 2002.
Celltrion Inc is headquartered in Korea South.
Celltrion Inc operates in Biotechnology and Pharmaceutical. Its work centres on Biopharmaceuticals, Monoclonal Antibody Biosimilars, Therapeutic Proteins and Innovative Medications. Its customers include Healthcare Providers, Patients and Pharmacy Benefit Managers (PBMs).
Celltrion Inc has a B2B, D2C and B2B2C business model. Its revenue comes from Product Sales, Licensing and Service Fee.
Celltrion Inc has approximately 2596 employees.
Celltrion Inc has completed 5 funding rounds, raising a total of $1.23B. The latest funding stage is IPO.
Celltrion Inc offers: Research and Development (R&D), Clinical Trials, Manufacturing and Production, Regulatory Affairs, Distribution and Sales.
Top alternatives and competitors to Celltrion Inc include Differentiated Therapeutics Inc, BlossomHill Therapeutics, Inc., Genmab, Skye Bioscience Inc., Seagen. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Celltrion Inc and Differentiated Therapeutics Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Celltrion Inc, https://bouncewatch.com/company/celltrion-inc, updated 8 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes